A. Eijkelboom

Treatment-free interval as a determinant of second-line chemotherapy outcomes in extensive-stage small cell lung cancer: a Dutch population-based study.

For patients with a CFI exceeding 90 days, platinum rechallenge represents a rational second-line treatment strategy and remains relevant despite the introduction of first-line chemoimmunotherapy, as a substantial proportion of patients still relapse within 180 days.